Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway

Fig. 3

MiR-634 mimic enhances chemotherapy sensitivity in primary ovarian cancer cell cultures. a Overexpression of miR-634 in primary ovarian cancer cell cultures, derived from the ascites of ovarian cancer patients, has no or a moderate effect on cell viability 72 h after transfection. Indicated is the viability of miR-634 transfected cells relative to the viability of cells transfected with scrambled mimic (set at 100 %). The numbers on the X-axis refer to the number of the culture. Depicted are average values ± SD (n = 3). b MiR-634 enhances the sensitivity for cisplatin. Depicted are the results of a representative experiment for culture 3 (left, n = 4) and culture 7 (right, n = 3). An overview of the results obtained for all cultures is in Additional file 1 Figure S4. * = p < 0.05, ** = p < 0.01. c MiR-634 enhances the sensitivity for carboplatin. Depicted are the results of a representative experiment for culture 3 (left, n = 3) and culture 7 (right, n = 4). An overview of all cultures that were treated with carboplatin is in Additional file 1: Figure S5. * = p < 0.05, d MiR-634 enhances the sensitivity for doxorubicin. Depicted are the results of a representative experiment for culture 3 (left, n = 3) and culture 7 (right, n = 3). ** = p < 0.01. e MiR-634 does not significantly alter the sensitivity for paclitaxel. Depicted are the results of a representative experiment for culture 3 (left, n = 3) and culture 7 (right, n = 3)

Back to article page